# Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines

> **NCT00478816** · PHASE2 · COMPLETED · sponsor: **Novartis Vaccines** · enrollment: 58 (actual)

## Conditions studied

- Prophylaxis of Avian Influenza Vaccine

## Interventions

- **BIOLOGICAL:** Fluad H5N1 Pandemic Influenza Vaccine

## Key facts

- **NCT ID:** NCT00478816
- **Lead sponsor:** Novartis Vaccines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-02
- **Final completion:** 2009-02
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2016-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00478816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00478816, "Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Adults Unprimed and Primed With Adjuvanted or Non-adjuvanted Influenza Vaccines". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00478816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*